Vanguard Capital Management’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.9M Buy
3,471,514
+205,983
+6% +$1.23M ﹤0.01% 2348
2026
Q2
$17.7M Sell
3,265,531
-211,250
-6% -$887K ﹤0.01% 2509
2026
Q1
$10.7M Buy
+3,476,781
New +$10.7M ﹤0.01% 2700

Other funds holding STLN

Vanguard Capital Management's STLN Position: Q3 2026 in Review

Vanguard Capital Management increased its Starling Oncology (STLN) stake by 6.3% in Q3 2026, buying an estimated $1.23M and bringing the position to 3,471,514 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2348.

Vanguard Capital Management first reported a position in STLN in Q1 2026 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • Vanguard Capital Management held 3,471,514 shares of Starling Oncology worth $21.9M as of Q3 2026.
  • Vanguard Capital Management bought 205,983 Starling Oncology shares in Q3 2026, an estimated $1.23M.
  • Starling Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2348 holding.
  • Vanguard Capital Management first reported a position in Starling Oncology in Q1 2026 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.